Researchers Develop App for Assessing Cognitive Function in Multiple Sclerosis
Researchers at Johns Hopkins Medicine developed an app for assessing cognitive function in multiple sclerosis.
Multiple Sclerosis
Neuroaxonal Damage in Pediatric Demyelinating Syndromes Linked to Neurofilament Light Chain
In pediatric patients with a first attack of acquired demyelinating syndrome, there exists a positive association between CSF and serum neurofilament light chain.
Study Identifies Predictors of Relapse in Children With First Demyelinating Event
Older age, brainstem syndrome, and polyfocal-specific magnetic resonance imaging presentation at onset are predictive of relapse risk in children with demyelinating diseases of the central nervous system.
The Apparent Slowing of Disability Progression in Multiple Sclerosis
Further understanding of the recently recognized symptomatic, measurable prodrome phase in multiple sclerosis will increase clinicians’ ability to diagnose and manage the disease earlier.
Immunosuppressive Therapy Prior to Pregnancy Not Associated With Negative Long-Term Outcomes in NMOSD
The use of immunosuppressive therapy (IST) prior to pregnancy in women with neuromyelitis optica spectrum disorder (NMOSD) is not associated with negative long-term outcomes.
Therapeutic Potential for Subcutaneous Ofatumumab in Relapsing Multiple Sclerosis
The results of the identically designed ASCLEPIOS I and II phase 3 trials evaluating the effect of ofatumumab versus teriflunomide in participants with relapsing multiple sclerosis were presented at ECTRIMS 2019.
Key Considerations for Establishing and Confirming Secondary Progressive MS Diagnosis
A high percentage of neurologists report diagnosing secondary progressive multiple sclerosis over a shorter period than that suggested by clinical guidance, and a greater number of neurologists who focus on multiple sclerosis diagnose and treat patients with SPMS than general neurologists.
Patient-Reported Outcome Measures for Understanding Fatigue in MS Remain Limited
Researchers find that a refinement of patient-reported outcome measures is needed to understand the drivers of underlying fatigue in patients with multiple sclerosis.
Ponesimod Superior to Teriflunomide in Relapsing MS Trial
Janssen announced results from the phase 3 OPTIMUM study comparing treatment with ponesimod vs teriflunomide in patients with relapsing multiple sclerosis.
Link Between Lesion Location and Obstructive Sleep Apnea in Multiple Sclerosis
The risk for development of obstructive sleep apnea (OSA) and the severity of disease in patients with multiple sclerosis (MS) may be affected by the location of the lesions.
Next post in ECTRIMS 2019
